Search bioRxivSearch

Biology subjects

Li, M.

Publications and source records attributed to Li, M..

2 recordsLinked to original sources

Beyond Imbalance: An Elasticity Framework for the Distance-averaged Force-Velocity Relationship in Vertical Jump

This study aimed to (1) establish the distance-averaged F-V relationship framework and (2) develop elasticity metrics that quantify how F-V relationship variables govern jump height and inform training prescription. Theoretical derivation and experimental validation across 108 F-V relationship models derived from 1578 jumps (countermovement jump and squat jump at three knee angles; 20 well-trained subjects) yielded a standard error of 2.1% and a nearly perfect correlation (r = 0.96, p < 0.001) between measured and predicted jump height. Four elasticity metrics were formulated: force elasticity (F_{e}), the elasticity of jump height to maximal force (F_{0}); velocity elasticity (v_{e}), the elasticity of jump height to maximal velocity (v_{0}); the force-velocity elasticity norm {(\mathrm{F}-\mathrm{V}}_{\mathrm{EN}}=\sqrt{F_{e}^{2}+v_{e}^{2}}), reflecting the overall sensitivity of jump height to changes in F-V relationship variables; and the force-velocity elasticity ratio {(\mathrm{F}-\mathrm{V}}_{\mathrm{ER}}=F_{e}{\div v}_{e}), indicating which variable dominates the jump height response. Simulations and experiments revealed that F_{e} bore an inverse relationship to F_{0}, and v_{e} was inversely related to v_{0}, reflecting diminishing marginal returns. At a fixed jump height, simulations showed {\mathrm{F}-\mathrm{V}}_{\mathrm{EN}} and {\mathrm{F}-\mathrm{V}}_{\mathrm{ER}} displayed a U-shaped relationship; a balanced profile ({\mathrm{F}-\mathrm{V}}_{\mathrm{ER}}=1) did not always correspond to the lowest {\mathrm{F}-\mathrm{V}}_{\mathrm{EN}}. The distance-averaged F-V elasticity framework offers a physically grounded and quantitative tool for linking F-V relationship variables directly to jump performance, providing a basis for informing individualized training decisions.

biophysics

Immunizing small cell lung cancer mice with isoaspartylated Elavl4 after chemotherapy mimics improved survival of anti-ELAVL4 antibody-positive small cell lung cancer patients

Introduction: Small cell lung cancer (SCLC) patients have an ~8% 5-year survival; new therapies are urgently needed. Approximately 15% of SCLC patients have naturally-occurring low-titer antibodies against neuronal ELAVL proteins, associated with improved response to therapy and significantly improved survival. We previously determined that the anti-ELAVL4 response is triggered by isoaspartylation in the unstructured ELAVL4 N-terminal region. Methods: We used a Tp53fl/fl;Rb1fl/fl inducible SCLC mouse model to test whether 1) immunization with isoaspartylated Elavl4 (isoAsp-Elavl4) prior to SCLC induction improves survival in the absence of any other treatment, and 2) immunization with isoAsp-Elavl4 following completion of 3 rounds of cisplatin+etoposide therapy improves survival. Immunizations contained incomplete Freund's adjuvant with either a recombinant N-terminal fragment of Elavl4 (amino acids 1-117), incubated under isoaspartyl-inducing conditions, or phosphate-buffered saline (used as the negative control, since Elavl4 spontaneously isoaspartylates). Mice were monitored by blinded assessors until euthanasia was indicated. Results: IsoAsp-Elavl4-immunized animals all became immune responsive, and spontaneous anti-isoAsp-Elavl4 antibodies were observed in 7% of the control animals. Kaplan-Meier analyses revealed that pre-SCLC immunization with isoAsp-ELAVL4 in the absence of other treatments did not affect survival. In contrast, immunization of SCLC mice following chemotherapy significantly improved survival. Conclusions: An anti-isoAsp-ELAVL4 response can be actively induced in mice and significantly increases SCLC survival when given following chemotherapy. This indicates that the anti-isoAsp-ELAVL4 immune response can be leveraged to develop new therapies for SCLC patients.

cancer biology